

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
(Multiple sheets used when necessary)	Examiner	Roy, Baisakhi
SHEET 1 OF 8	Attorney Docket No.	EKOS.8CP1C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/B.R./	1	2,961,382	11-22-1960	H.O. Singher et al	
	2	3,565,062	02-23-1971	Kuris	
	3	4,027,659	06-07-1977	Slingluff	
	4	4,466,442	08-21-1984	Hilmann et al.	
	5	4,512,762	04-23-1985	Spears	
	6	4,573,470	03-04-1986	Samson, et al	
	7	4,582,067	04-15-1986	Silverstein et al	
	8	4,657,543	04-14-1987	Langer et al.	
	9	4,657,756	04-14-1987	Rasor et al.	
	10	4,692,139	09-08-1987	Stiles	
	11	4,697,595	10-06-1987	Breyer et al.	
	12	4,698,058	10-06-1987	Greenfeld, et al	
	13	4,710,192	12-01-1987	Liotta, et al	
	14	4,750,902	06-14-1988	Wuchinich et al	
	15	4,762,915	08-09-1988	Kung et al.	
	16	4,767,402	08-30-1988	Kost et al	
	17	4,772,594	09-20-1988	Hashimoto et al.	
	18	4,774,958	10-04-1988	Feinstein	
	19	4,797,285	01-10-1989	Barenholz et al.	
	20	4,821,740	04-18-1983	Tachibana, et al	
	21	4,844,882	07-04-1989	Widder et al.	
	22	4,870,953	10-03-1989	Don Michael et al	
	23	4,877,031	10-31-1989	Conway et al	
	24	4,900,540	02-13-1990	Ryan et al.	
	25	4,917,088	04-17-1990	Crittendon	
	26	4,917,102	04-17-1990	Miller et al	
	27	4,948,587	08-14-1990	Kost, et al	
/B.R./	28	4,953,565	09-04-1990	Tachibana, et al	

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
(Multiple sheets used when necessary)	Examiner	Roy, Baisakhi
SHEET 2 OF 8	Attorney Docket No.	EKOS.8CP1C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/B.R./	29	4,955,863	09-11-1990	Walker et al	
	30	4,971,991	11-20-1990	Umemura et al	
	31	4,992,257	02-12-1991	Bonnett et al	
	32	5,007,898	04-16-1991	Rosenbluth, et al	
	33	5,040,537	08-20-1991	Katakura	
	34	5,053,044	10-01-1991	Mueller, et al	
	35	5,085,662	02-04-1992	Willard	
	36	5,117,831	06-02-1992	Jang, et al	
	37	5,121,749	06-16-1992	Nassi et al.	
	38	5,149,319	09-22-1992	Unger	
	39	5,156,050	10-20-1992	Schmid et al.	
	40	5,181,920	01-26-1993	Mueller, et al	
	41	5,209,720	05-11-1993	Unger	
	42	5,215,680	06-01-1993	D'Arrigo	
	43	5,216,130	06-01-1993	Line et al.	
	44	5,269,297	12-14-1993	Weng, et al	
	45	5,277,913	01-11-1994	Thompson et al	
	46	5,279,546	01-18-1994	Mische, et al	
	47	5,315,998	05-31-1994	Tachibana, et al	
	48	5,324,225	06-28-1994	Passafaro, et al	
	49	5,344,395	09-06-1994	Whalen, et al	
	50	5,415,636	05-16-1995	Forman	
	51	5,419,763	05-30-1995	Hildebrand	
	52	5,489,279	02-06-1996	Meserol	
	53	5,542,935	08-06-1996	Unger, et al	
	54	5,558,092	09-24-1996	Unger, et al	
	55	5,558,642	09-24-1996	Schweich, Jr., et al	
/B.R./	56	5,567,687	10-22-1996	Magda et al	

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
(Multiple sheets used when necessary)	Examiner	Roy, Baisakhi
SHEET 3 OF 8	Attorney Docket No.	EKOS.8CP1C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/B.R./	57	5,569,198	10-29-1996	Racchini	
	58	5,580,575	12-03-1996	Unger et al.	
	59	5,585,112	12-17-1996	Unger et al.	
	60	5,586,982	12-24-1996	Abela	
	61	5,588,962	12-31-1996	Nicholas, et al	
	62	5,594,136	01-14-1997	Sessler et al	
	63	5,609,574	03-11-1997	Kaplan, et al	
	64	5,616,342	04-01-1997	Lyons	
	65	5,632,970	05-27-1997	Malinowski et al	
	66	5,648,098	07-15-1997	Porter	
	67	5,663,327	09-02-1997	Tarabo et al	
	68	5,707,608	01-13-1998	Liu	
	69	5,718,921	02-17-1998	Mathiowitz et al.	
	70	5,733,572	03-31-1998	Unger, et al	
	71	5,766,902	06-16-1998	Craig, et al	
	72	5,776,429	07-07-1998	Unger et al.	
	73	5,817,048	10-06-1998	Lawandy	
	74	5,849,727	12-15-1998	Porter, et al	
	75	5,876,989	03-02-1999	Berg et al	
	76	5,895,358	04-20-1999	Becker et al.	
	77	5,895,398	04-20-1999	Wensel, et al.	
	78	5,922,687	07-13-1999	Mann, et al	
	79	5,925,016	07-20-1999	Chornenky, et al	
	80	5,938,595	08-17-1999	Glass, et al	
	81	6,030,374	02-29-2000	McDaniel	
	82	6,068,857	05-30-2000	Weitschies et al.	
	83	6,117,858	09-12-2000	Porter, et al	
/B.R./	84	6,135,976	10-24-2000	Tachibana, et al	

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
(Multiple sheets used when necessary)	Examiner	Roy, Baisakhi
SHEET 4 OF 8	Attorney Docket No.	EKOS.8CP1C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/B.R./	85	6,245,747	06-12-2001	Porter, et al	
	86	6,295,990	10-02-2001	Lewis, et al	
	87	6,346,098	02-12-2002	Yock, et al	
	88	6,372,498	04-16-2002	Newman, et al	
	89	6,416,740	07-09-2002	Unger	
	90	6,461,296	10-08-2002	Ashvin H. Desai	
	91	6,461,383	10-08-2002	Gesswein, et al	
	92	6,485,853	07-30-2002	Edwards	
	93	6,508,816	01-21-2003	Shaddock	
	94	6,524,251	02-25-2003	Rabiner et al.	
	95	6,527,761	03-04-2003	Soltesz, et al	
	96	6,548,047	04-15-2003	Unger	
	97	6,551,337	04-22-2003	Rabiner, et al	
	98	6,582,392	06-24-2003	Bennett et al	
	99	6,652,581	11-25-2003	Ding	
	100	6,680,301	01-20-2004	Berg et al	
	101	6,723,063	04-20-2004	Zhang, et al	
	102	6,797,293	12-27-2005	Hansmann, et al.	
	103	6,921,371	07-26-2005	Wilson	
	104	6,958,040	10-25-2005	Oliver, et al	
	105	6,958,059	10-25-2005	Zadno-Azizi	
	106	7,141,044	11-28-2006	Gentsler	
	107	2001/0003790	06-14-2001	Ben-Haim et al.	
	108	2001/0007666	07-12-2001	Hoffman, et al	
	109	2001/0053384	12-20-2001	Greenleaf, et al	
	110	2002/0032394	03-14-2002	Brisken, et al	
	111	2002/0068717	06-06-2002	Borrelli	
/B.R./	112	2002/0151792	10-17-2002	Conston et al.	

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
(Multiple sheets used when necessary)	Examiner	Roy, Baisakhi
SHEET 5 OF 8	Attorney Docket No.	EKOS.8CP1C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/B.R./	113	2003/0069525	04-10-2003	Briskin, et al	
/B.R./	114	2004/0024347	02-05-2004	Wilson, et al	
/B.R./	115	2004/0039329	02-26-2004	Ueberle	
/B.R./	116	2004/0106847	06-03-2004	Shaw, et al	
/B.R./	117	2005/0027247	02-03-2005	Carrison, et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/B.R./	118	DE 39 19 592 A1	02-22-1990	Olympus Optical Co., Ltd.		
	119	EP 0 189 329	07-30-1986	Fischell, et al		
	120	EP 1 252 885	10-30-2002	Imarx Pharmaceutical Corp.		
	121	EP 668052A2	02-17-1995	Olympus Optical Co., Ltd.		
	122	WO 89/05160	06-15-1989	Schering AG Berlin Und Bergkamen		X-abs
	123	WO 92/07622	05-14-1992	BSD Medical Corporation		
	124	WO 93/08738	05-13-1993	Mayo Foundation for Medical Education and Research		
	125	WO 95/15118	06-08-1995	Unger et al.		
	126	WO 96/07432	03-14-1996	Radiumhospitalets Forskningsstiftelse		
	127	WO 96/15815	05-30-1996	Bracco Research S.A.		
	128	WO 98/58699	12-30-1998	Ekos Corporation		
	129	WO 99/33500	07-08-1999	Pharmasonics, Inc.		
	130	WO 99/34858	07-15-1999	Georgia Tech Research Corp.		
/B.R./	131	WO 99/39738	08-12-1999	Bracco Research S.A.		

NON PATENT LITERATURE DOCUMENTS

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i> SHEET 6 OF 8	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
	Examiner	Roy, Baisakhi
	Attorney Docket No.	EKOS.8CP1C1

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/B.R./	132	AKHTAR, Anti-HIV therapy with antisense oligonucleotides and ribozymes: realistic approaches or expensive myths? (J. Antimicrob Chemother. 38(2): 159-165, 1996)	
	133	ANDERSON, Human gene therapy. (Nature 392:25-30, 1998)	
	134	B.D. BUTLER, J. clin. Ultrasound 14(5): 408-12 (Jun. 1986) Production of Microbubbles for Use as Echo Contrast Agents*.	
	135	Bao, et al. "Transfection of a Reporter Plasmid into Cultured Cells by Sonoporation In Vitro," Ultrasound in Med. and Biol., Vol. 23, No. 6, pp. 953-	
	136	BLEEKER et al., J. Ultrasound, Med. 9(8): 461-71 (Aug. 1990) On the Application of Ultrasonic Contrast Agents for Blood Flowmetry and Assessment of Cardiac Perfusion*.	
	137	BRANCH, A Good Antisense Molecule is Hard to Find, (Trends in Biochem Sci 23: 45-50, 1998)	
	138	Cancer Letters, Vol. 72, 1993, pp. 195-199, Tachibana	
	139	Cancer Letters, Vol. 78 (1-3), 1994, pp.177-181, Tachibana	
	140	CROOKE, Basic Principles of Antisense Therapeutics (Springer-Verlag, Eds, New York, 1998, pgs. 1 and 4)	
	141	Fechmeier, et al. "Transfection of Mammalian Cells with Plasmid DNA by Scrape Loading and Sonication Loading," Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 8463-8467, December 1987	
	142	FEINSTEIN et al., J. Am. Coll. Cardiol. 3(1): 14-20 (Jan. 1984) Two-dimensional Contrast Echocardiography I. In Vitro Development and Quantitative Analysis of Echo Contrast Agents*.	
	143	Feldman, et al. "Optimal Techniques for Arterial Gene Transfer," Cardiovascular Research, 35 (1997) pp. 391-404	
	144	Maywald G. et al., "Experience With Atraumatic Vascular Diagnosis With The Aid of the Ultrasonic Doppler Technique", Electromedica, Vol. 2 pp. 43-48 (1976)	
	145	GREENLEAF, William J. et al.; Artificial Cavitation Nuclei Significantly Enhance Acoustically Induced Cell Transfection. Vol. 24, No. 4 pp. 587-595, 1998.	
	146	HO and PARKINSON, Antisense Oligonucleotides and Therapeutics for Malignant Diseases, (Seminars in Drug Discovery 24(2): 187-202, 1997)	
	147	HOLLAND, C.K. and R.E. APFEL, J. Acoust. Soc. Am. 88(5): 2059-2069 (Nov. 1990) Thresholds for Transient Cavitation Produced by Pulsed Ultrasound in a Controlled Nuclei Environment*.	
	148	Yumita N., Japanese Journal of Cancer Research, Vol. 81, No. 3, March 1990, pp. 304-8	
	149	JEFFERS, R.J. et al.; Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms, 1993.	
/B.R./	150	JEFFERS, Russel et al; Dimethylformamide as an Enhancer of Cavitation-Induced Cell Lysis In Vitro, Vol. 97, No. 1, Jan. 1995.	

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i> SHEET 7 OF 8	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
	Examiner	Roy, Baisakhi
	Attorney Docket No.	EKOS.8CP1C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/B.R./	151	KELLER et al., J. Ultrasound Med. 5(9): 493-8 (Sept. 1986) Automated Production and Analysis of Echo Contrast Agents*.	
	152	Kim, et al. "Ultra-sound Mediated Transfection of Mammalian Cells," Human Gene Therapy, 7: 1339-1346 (July 10, 1996)	
	153	KIM, T.F. Medical news & Perspectives, JAMA 261(11): 1542 (Mar. 17, 1989) Microbubbles Show Promise for Enhancing Ultrasound Signal, Image, Other Applications*.	
	154	Kotnis, et al. "Optimisation of Gene Transfer into Vascular Endothelial Cells Using Electroporation," Eur J. Vasc Surg, 9, 71-79 (1995)	
	155	LANG et al., Circulation 75(1): 229-234 (Jan. 1987) Contrast Ultrasonography of the Kidney: a New Method for Evaluation of Renal Perfusion in Vivo*.	
	156	LEONG et al., Biomaterials, vol.7: 364-371 (Sept. 1986) Polyanhydrides for Controlled Release of Bioactive Agents*.	
	157	MELTZER et al., J. Clin. Ultrasound 8(2): 121-7 (Apr. 1980) The Source of Ultrasound Contrast Effect*.	
	158	MILLER, Douglas L. et al.; Sonoporation of Cultured Cells in the Rotation Tube Exposure System, vol. 25, No. 1, 1999.	
	159	ORKIN and MOTULSKY, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, (p 1-38, 12/7/1995)	
	160	PCT Search Report, PCT Application PCT/US2006/13531; 12 April 2006	
	161	Porter, et al "Interaction of Diagnostic Ultrasound with Synthetic Oligonucleotide-Labeled Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles," J Ultrasound Med, 15:557-584, 1996	
	162	PORTER, T.R. et al., Thrombolytic Enhancement With Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles, Nov. 1996.	
	163	PRAT, F. et al.; In Vivo Effects of Cavitation Alone or in Combination With Chemotherapy in a Peritoneal Carcinomatosis in the Rat. Vol. 68, pp. 13-17	
	164	PRICE, Richard et al.; Delivery of Colloidal Particles and Red Blood Cells to Tissue Through Microvessel Ruptures Created By Targeted Microbubble Destruction With Ultrasound, Sep. 29, 1998.	
	165	ROMANO et al., Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications, (Stem Cells 18: 19-39, 2000)	
	166	Rosenschein, U. et al., "Experimental Ultrasonic Angioplasty: Disruption of Atherosclerotic Plaques and Thrombi in Vitro and Arterial Recanalization in	
	167	SOMIA and VERMA, Gene Therapy: Trials and Tribulations, (Nature Reviews Genetics 1:91-99, 2000)	
/B.R./	168	TACHIBANA K.; Albumin Microbubble Echo-Contrast Materials as an Enhancer For Ultrasound Accelerated Thrombolysis, Sep.1, 1995.	

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i> SHEET 8 OF 8	Application No.	10/735588
	Filing Date	12-12-2003
	First Named Inventor	Frederick J. Bennett, et al.
	Art Unit	3737
	Examiner	Roy, Baisakhi
	Attorney Docket No.	EKOS.8CP1C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/B.R./	169	Tachibana, K. "Enhancement of Fibrinolysis with Ultrasound Energy", JVIR, Vol. 3, No. 2, May 1992, pp. 299-303	
	170	Tsurumi, et al. "Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion," Circulation, 1996; 94: 3281-3290	
	171	Unger, et al. "Ultrasound Enhances Gene Expression of Liposomal Transfection," Investigative Radiology, Vol. 32, No. 12, pp. 723-727, 1997	
	172	UNGER, EVAN C. et al.; Acoustically Active Liposheres Containing Paclitaxel, vol. 11, No. 12, 1992.	
	173	VANDENBURG et al., Am. Heart J., 115(4), 733-9 (Apr. 1988) Myocardial Risk Area and Peak Gray Level Measurement by Contrast Echocardiography: Effect of Microbubble Size and Concentration, Injection Rate, and Coronary Vasodilation*.	
	174	VERMA et al., Gene Therapy – promises, problems and prospects, (Nature 389: 239-242, 1997)	
	175	WHEATLY et al., Biomaterials 11(19): 713-7 (Nov. 1990) Contrast Agents for Diagnostic Ultrasound: Development and Evaluation of Polymer-Coated Microbubbles*.	
	176	WU, Yunqiu et al., Binding as Lysing of Blood Clots Using MRX-408, May 1998.	
/B.R./	177	Wyber, et al. "The Use of Sonication for the Efficient Delivery of Plasmid DNA into Cells," Pharmaceutical Research, Vol. 14, No. 6, pp. 750-756	

9254987
062410

Examiner Signature /Baisakhi Roy/	Date Considered 09/07/2010
-----------------------------------	----------------------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language translation is attached. **ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.R./**